低总蛋白质预测慢性阻塞性肺病患者的不良结果
Yiben Huang1, Jianing Wang1,2, Zicong Dai1,2
1Department of Respiratory and Critical Medicine, The Third Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China.
Sleep & breathing = Schlaf & Atmung
|June 4, 2025
概括
慢性阻塞性肺病 (COPD) 患者的较低总蛋白 (TP) 水平表明疾病严重程度增加. 这种随时可用的指标也与运动耐受性相关,为COPD进展提供了洞察力.
科学领域:
- 肺部医学 肺部医学
- 临床生物化学 临床生物化学
背景情况:
- 总蛋白 (TP),包括白蛋白和血球蛋白,是一种广泛可用的生物标志物.
- 慢性阻塞性肺病 (COPD) 是一种渐进的呼吸道疾病,疾病严重程度和运动耐受性是关键的临床指标.
研究的目的:
- 调查总蛋白质水平与稳定慢性阻塞性肺病 (COPD) 严重程度之间的关联.
- 评估COPD患者的总蛋白质和运动耐受性之间的相关性.
主要方法:
- 分析了84名COPD患者的血总蛋白质水平,体重指数,气流阻塞,呼吸困难,运动能力指数 (BODE) 和六分钟步行距离 (6MWD).
- 根据TP水平,患者被分为三层.
- 采用接收器运行特征 (ROC) 曲线和后勤回归分析来评估TP对严重COPD (BODE ≥5) 的预测性能及其与BODE等级的独立关联.
主要成果:
- 较低的TP水平 (<61.2) 与较高比例的严重COPD显著相关.
- 与白蛋白和球蛋白相比,TP在预测高BODE指数方面表现出最高的准确性 (AUC = 0.789).
- 在入院后的最初30天内,TP水平与6MWD呈正相关性.
结论:
- 降低总蛋白质水平与COPD严重程度的增加有关,由更高的BODE指数表明.
- 总蛋白质作为COPD严重程度的有价值和准确的预测指标,可能与运动能力相关.
相关概念视频
01:22Chronic Obstructive Pulmonary Disease
1.4K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
1.4K
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
3.1K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
3.1K
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
2.9K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
2.9K
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
2.6K
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Medical History
2.6K
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
3.0K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
3.0K
01:29Factors Affecting Protein-Drug Binding: Patient-Related Factors
123
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
123